Mumcuoglu M, Zakay-Rones Z, Weiss L, Slavin S
Department of Bone Marrow Transplantation and Cancer, Hadassah University Hospital, Jerusalem, Israel.
Exp Hematol. 1996 Nov;24(13):1516-20.
Treatment with recombinant human IL-2 (rIL-2) is being investigated as a new modality for the control of minimal residual disease in conjunction with autologous bone marrow transplantation for a variety of malignant hematological disorders and certain solid tumors. In investigating the functional role of rIL-2 in T cell dependent humoral immune responses, we determined the level of IgG, IgM, and total antibodies activity in BALB/c mice, with or without rIL-2 administration, before primary or secondary immunization with sheep red blood cells (SRBC) or influenza virus A/PR8/34 (H1N1). Our results show the beneficial effect of pretreatment with rIL-2 in enhancing primary and secondary humoral immune responses to SRBC (p < 0.05) and possibly to influenza virus. Administration of well tolerated doses of rIL-2 before inoculation of antigen or infectious agent is not likely to be harmful and may even enhance protective immunological responses.
重组人白细胞介素-2（rIL-2）治疗作为一种新的治疗方式，正与自体骨髓移植联合用于控制多种恶性血液疾病和某些实体瘤的微小残留病。在研究rIL-2在T细胞依赖性体液免疫反应中的功能作用时，我们测定了在对绵羊红细胞（SRBC）或甲型流感病毒A/PR8/34（H1N1）进行初次或二次免疫之前，给予或未给予rIL-2的BALB/c小鼠的IgG、IgM水平以及总抗体活性。我们的结果显示，rIL-2预处理对增强针对SRBC的初次和二次体液免疫反应具有有益作用（p<0.05），对流感病毒可能也有作用。在接种抗原或感染因子之前给予耐受性良好剂量的rIL-2不太可能有害，甚至可能增强保护性免疫反应。
